Product Information
LEVOCETIRIZINE 2.5 MG/5 ML SOL is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.1659 per ML under NDC 45802068028. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 7, 2011. Its Orange Book therapeutic-equivalence code is AA.
Strength
.5 mg/mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802068028
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOCETIRIZINE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091263FDA Approved
11/7/2011
TE Code
AA
On Market Since
11/7/2011
Pharmacological Classes
Price Statistics
The NADAC for LEVOCETIRIZINE 2.5 MG/5 ML SOL has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 60.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1659 per ML |
|---|---|
| All-time high | $0.5031 (Apr 15, 2015) |
| All-time low | $0.1171 (Sep 22, 2021) |
| 52-week high | $0.1690 |
| 52-week low | $0.1409 |
| Median price | $0.3186 |
| Average price | $0.3171 |
| Largest weekly change | +68.3% (Dec 22, 2021) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Levocetirizine dihydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levocetirizine dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOCETIRIZINE 2.5 MG/5 ML SOL?
The current National Average Drug Acquisition Cost (NADAC) for LEVOCETIRIZINE 2.5 MG/5 ML SOL, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.1659 per ML (NDC 45802068028), effective Sep 30, 2026.
How has the price of LEVOCETIRIZINE 2.5 MG/5 ML SOL changed over time?
Over the history we have for it, the NADAC for LEVOCETIRIZINE 2.5 MG/5 ML SOL has declined 60.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LEVOCETIRIZINE 2.5 MG/5 ML SOL?
Since Nov 28, 2013, the NADAC for LEVOCETIRIZINE 2.5 MG/5 ML SOL has ranged from a low of $0.1171 (Sep 22, 2021) to a high of $0.5031 (Apr 15, 2015), with a median of $0.3186 per ML.
Are there cheaper alternatives to LEVOCETIRIZINE 2.5 MG/5 ML SOL?
No other NADAC-published product currently shares the active ingredient and strength of LEVOCETIRIZINE 2.5 MG/5 ML SOL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LEVOCETIRIZINE 2.5 MG/5 ML SOL?
LEVOCETIRIZINE 2.5 MG/5 ML SOL (NDC 45802068028) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.